Johnson & Johnson (NYSE:JNJ) shareholders filed a derivatives lawsuit over $78 million in settlements the company paid to put over Foreign Corrupt Practices Act violation and kickback charges to rest.
depuysynthes
Zimmer’s hips swing in Q1
Zimmer Holdings Inc. (NYSE:ZMH) flexed its muscles in the hip business, riding strong sales in one of its key markets to a 5 percent jump in overall sales during the first quarter.
The Warsaw, Ind.-based orthopedic maker posted a $209 million profit on $1.11 billion in sales during the three months ended March 31, a 2 percent increase over the $205 million in net income on $1.06 billion in sales posted during the same period last year.
Synthes stays flat, Johnson and Johnson ticks down on $21 billion buyout
DePuy hip recall: New Jersey benefits fund sues Johnson & Johnson
A fund that manages health benefits for 25 towns in northern New Jersey filed a class action lawsuit against Johnson & Johnson (NYSE:JNJ) subsidiary DePuy Orthopaedics over its massive ASR hip implant recall.
In a civil suit filed in U.S. District Court for New Jersey late last week, the North Jersey Municipal Employee Benefits Fund accused J&J of fraud and unjust enrichment, alleging that the New Brunswick, NJ.-based medical conglomerate knew of problems with the implant but left it on the U.S. market anyway.
Synthes takeover could be the orthopedics makeover that Johnson & Johnson needs
MASSDEVICE ON CALL — Johnson & Johnson’s (NYSE:JNJ) may be looking at its proposed mega-merger with Synthes as a way to save its orthopedics business.
Johnson & Johnson’s Q1 profits slides 23 percent as Synthes confirms merger talks
Johnson & Johnson (NYSE:JNJ) may have a monster fish on the hook, but it’s still got some work to do on its bottom line after watching its profits drop 23 percent during the first three months of 2011.
Report: Johnson and Johnson in talks to buy Synthes for $20 billion
Johnson & Johnson (NYSE:JNJ) is in talks to buy Synthes Inc. for $20 billion, according to a report in the Wall Street Journal.
DePuy hip recall: Patient shares horror story with Senate panel
More than 96,000 patients have been affected by the massive global recall of a total hip replacement system made by DePuy Orthopaedics, Inc. Katie Korgaokar, one of those unlucky patients, spoke for all of them today at a U.S. Senate hearing on medical device safety.
“I thought I was getting good advice. I researched the doctor. I picked him. I just don’t know what I could’ve done differently,” she said. “It still blows me away that something that goes into the body doesn’t get tested properly.”
Johnson & Johnson bribery case: Company slipped millions in fines ratting out competitors
Johnson & Johnson (NYSE:JNJ) saved millions in criminal fines for providing federal prosecutors with information on its competitors’ transgressions, according to a U.S. Dept. of Justice press release.
DePuy hip recall: Senate to probe safety of medical devices
This week isn’t going to get any better for DePuy Inc., as the Johnson & Johnson (NYSE:JNJ) subsidiary is set to have its dirty laundry aired in front of a Senate panel tomorrow.
The U.S. Senate’s Special Committee on Aging announced that the Warsaw, Ind.-based company’s massive hip replacement system recall will be front and center during its examination of the FDA and its role in “protecting patient safety as part of the medical device approval process,” according to a prepared release.
DePuy at the center of $70 million Johnson & Johnson bribery beef
DePuy Inc. allegedly earned more than $24 million in profits over eight years by bribing Greek orthopedic surgeons to buy its implants, according to a federal investigation that resulted in Johnson & Johnson (NYSE:JNJ) agreeing to pay $70 million in fines in a deferred prosecution agreement in the U.S. and more than $8 million in the U.K.